Since March 2017, the side effects, sometimes serious , reported by thousands of patients treated with the new formula of Levothyrox for thyroid disorders have continued to multiply ... and worry.

And it is not the investigation "The 13 dead Levothyrox hidden by the French authorities" magazine "Ebdo", whose release in newsstands is scheduled for January, which may appease their fears.

According to his information, these deaths were recorded in the national database listing the adverse effects of drugs in recent months. Cautious, the weekly still specifies that "for each of them, the link of cause and effect between the taking of the drug and the death is not established", but that "the absence of link is not not established either! "

Four deaths already mentioned by the ANSM in October 2017

Wednesday, November 29, 2017, this figure was, partly since revised upwards, confirmed by the National Agency of Health Products and Medicines (ANSM), which reacted via his Twitter account: "As of November 20, 14 842 These cases were seized from the national pharmacovigilance database, including 14 deaths with no link to Levothyrox, and these patients received several treatments and most of them suffered serious illnesses. " In addition, she adds that "the reports of deaths and serious cases are systematically subject to special vigilance of the ANSM.If a link is established with the Levothyrox the ANSM will take the necessary measures."

In a report written by the Rennes Drug Monitoring Center and made public on October 10, 2017, four deaths among the 5062 reported cases and 25 151 adverse reactions identified had already been mentioned, without establishing a formal link with the Levothyrox: "a case of cardiorespiratory arrest in a patient of 34 years receiving heavy psychiatric treatment (...) a case of sudden death in a woman of 78 years (...) a case of 39-year-old woman in which a diagnosis of thyroiditis Hashimoto is posed in July 2017 (...) deaths one month later in a chart of pulmonary edema with heart failure (...) a case of ischemic stroke in an 87-year-old diabetic woman " .

To shed light on this case, "Ebdo" believes that "to clear (or not), the new formula of Levothyrox in these thirteen deaths listed, requires a judicial inquiry."

To date, hundreds of patient complaints have been filed in several regions. Since September 15, a preliminary investigation has been opened and entrusted to the public health unit of the Tribunal de Grande Instance of Marseille. In total, three million people are currently treated by Levothyrox in France.